Amgen Files Denosumab Biologics License Application To FDA
Amgen’s Denosumab is a fully human monoclonal antibody in late stage clinical development that specifically targets Rank Ligand, the essential regulator of osteoclasts (the cells that break down
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.